Jump to content

Olamkicept

Add links
From Wikipedia, the free encyclopedia
Olamkicept
Identifiers
UNII
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Olamkicept, also known as soluble gp130Fc or sgp130Fc (other designations are FE 999301, FE301, TJ301) is an immunosuppressive drug candidate, which selectively blocks activities of the cytokine Interleukin-6, which are mediated by the soluble Interleukin-6.[1] Interleukin-6 is a cytokine, which plays a dominant role in the regulation of the immune response and also in autoimmunity. Furthermore, Interleukin-6 has been demonstrated to be involved in the regulation of metabolism and body weight.[2] Interleukin-6 also has many activities on neural cells.[3] The biochemical principle was invented by the German biochemist Stefan Rose-John and it was further developed into a biotech compound by the Conaris Research Institute AG, which gave an exclusive world-wide license to the Swiss-based biopharmaceutical company Ferring Pharmaceuticals.[4] In December 2016, Ferring and the biotech company I-MAB signed a licensing agreement granting I-MAB exclusive rights in Asia to Olamkicept for the treatment of autoimmune disease.[5]

Mechanism of action

[edit]

On cells, interleukin-6 binds to an Interleukin-6 receptor, which, however, is not signaling.[6] The complex of Interleukin-6 and the Interleukin-6 receptor binds to a second receptor protein, gp130, which thereupon dimerizes and initiates intracellular signaling.[7] The gp130 receptor is present on all cells of the human body, whereas the Interleukin-6 receptor is only expressed by some cells such as hepatocytes, epithelial cells and some[7] leukocytes. Since Interleukin-6 exhibits only measurable affinity to the Interleukin-6 receptor but not to gp130, only cells, which express the Interleukin-6 receptor can respond to Interleukin-6. It was found that the Interleukin-6 receptor can be cleaved from the cell membrane by the protease ADAM17 generating a soluble[8] receptor. The soluble interleukin-6 receptor can still bind interleukin-6 and the complex of interleukin-6 and interleukin-6 receptor can bind to gp130 even on cells which do not express the membrane-bound interleukin-6 receptor. This mode of signaling has named Interleukin-6 trans-signaling.[9] The protein olamkicept consists of the extracellular portion of gp130 fused (and thereby dimerized) to the constant portion of a human IgG1 antibody. Like membrane bound gp130, the protein olamkicept does not bind Interleukin-6 alone but only the complex of interleukin-6 and soluble interleukin-6 receptor. Therefore, olamkicept only inhibits interleukin-6 trans-signaling but not interleukin-6 signaling via the membrane-bound interleukin-6 receptor.[10] It has been shown that Interleukin-6 activities via the membrane-bound interleukin-6 receptor are regenerative and protect from bacterial infections whereas interleukin-6 activities via the soluble interleukin-6 receptor are considered pro-inflammatory.[11] Therefore, olamkicept only blocks the pro-inflammatory activities of the cytokine interleukin-6.

Research

[edit]

In many animal disease models of human pathologies it was tested whether the specific blockade of interleukin-6 trans-signaling by the olamkicept protein was superior to a global blockade with an interleukin-6 or an interleukin-6 receptor neutralizing antibody.[12] It turned out that the specific blockade of Interleukin-6 trans-signaling was superior to global Interleukin-6 blockade in models of e.g. sepsis,[13] of acute lung injury after severe acute pancreatitis[14] and of abdominal aortic aneurysm.[15] Furthermore, it was shown that Interleukin-6 trans-signaling plays a dominant role in colon cancer[16] and lung cancer.[17]

Medical use

[edit]

The olamkicept protein underwent phase I clinical studies in healthy volunteers and a small cohort of largely inactive patients with IBD in 2013/14. An open label phase IIa study in patients with active inflammatory bowel disesase was performed in Germany.[18] A second placebo-controlled, phase II clinical trial in patients with ulcerative colitis was successfully completed in China, Taiwan and South Korea.[19] The results of the German phase IIa clinical trial were published and demonstrated target engagement through olamkicept exposure over 12 weeks in patients with active inflammatory bowel disease. Most interestingly some patients developed a complete remission while others went into response. The molecular analysis revealed an olamkicept-specific signature in influencing disease pathophysiology.[20] The results of the placebo controlled trial in China/Taiwan/South Korea were released during the 2021 Digestive Disease Week (DDW) and the 2021 annual meeting of the European Crohn’s and Colitis Organization (ECCO).[21]

References

[edit]
  1. ^ Jones, S. A.; Scheller, J.; Rose-John, S. (2011). "Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. - PubMed - NCBI". The Journal of Clinical Investigation. 121 (9): 3375–83. doi:10.1172/JCI57158. PMC 3163962. PMID 21881215.
  2. ^ Febbraio, M. A.; Rose-John, S.; Pedersen, B. K. (April 20, 2010). "Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases?". Clinical Pharmacology and Therapeutics. 87 (4): 396–398. doi:10.1038/clpt.2010.1. PMID 20305672. S2CID 7673109.
  3. ^ Rothaug, M.; Becker-Pauly, C.; Rose-John, S. (2016). "The role of interleukin-6 signaling in nervous tissue. - PubMed - NCBI". Biochimica et Biophysica Acta. 1863 (6 Pt A): 1218–27. doi:10.1016/j.bbamcr.2016.03.018. PMID 27016501.
  4. ^ "Ferring" (PDF).
  5. ^ "Ferring and IMAB sign licensing agreement granting IMAB exclusive rights in Asia to olamkicept for the treatment of autoimmune disease". December 19, 2016.
  6. ^ Yamasaki, K.; Taga, T.; Hirata, Y.; Yawata, H.; Kawanishi, Y.; Seed, B.; Taniguchi, T.; Hirano, T.; Kishimoto, T. (1988). "Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. - PubMed - NCBI". Science. 241 (4867): 825–8. doi:10.1126/science.3136546. PMID 3136546.
  7. ^ a b Taga, T.; Kishimoto, T. (April 20, 1997). "Gp130 and the interleukin-6 family of cytokines". Annual Review of Immunology. 15: 797–819. doi:10.1146/annurev.immunol.15.1.797. PMID 9143707.
  8. ^ Müllberg, J.; Schooltink, H.; Stoyan, T.; Günther, M.; Graeve, L.; Buse, G.; Mackiewicz, A.; Heinrich, P. C.; Rose-John, S. (February 20, 1993). "The soluble interleukin-6 receptor is generated by shedding". European Journal of Immunology. 23 (2): 473–480. doi:10.1002/eji.1830230226. PMID 8436181. S2CID 22834660.
  9. ^ Rose-John, S.; Heinrich, P. C. (1994). "Soluble receptors for cytokines and growth factors: generation and biological function. - PubMed - NCBI". The Biochemical Journal. 300 ( Pt 2) (Pt 2): 281–90. doi:10.1042/bj3000281. PMC 1138158. PMID 8002928.
  10. ^ Jostock, T.; Müllberg, J.; Ozbek, S.; Atreya, R.; Blinn, G.; Voltz, N.; Fischer, M.; Neurath, M. F.; Rose-John, S. (January 20, 2001). "Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses". European Journal of Biochemistry. 268 (1): 160–167. doi:10.1046/j.1432-1327.2001.01867.x. PMID 11121117.
  11. ^ Scheller, Jürgen; Chalaris, Athena; Schmidt-Arras, Dirk; Rose-John, Stefan (May 20, 2011). "The pro- and anti-inflammatory properties of the cytokine interleukin-6". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1813 (5): 878–888. doi:10.1016/j.bbamcr.2011.01.034. PMID 21296109.
  12. ^ Garbers, Christoph; Heink, Sylvia; Korn, Thomas; Rose-John, Stefan (June 20, 2018). "Interleukin-6: designing specific therapeutics for a complex cytokine". Nature Reviews. Drug Discovery. 17 (6): 395–412. doi:10.1038/nrd.2018.45. PMID 29725131. S2CID 19238101.
  13. ^ Barkhausen, Tanja; Tschernig, Thomas; Rosenstiel, Philip; van Griensven, Martijn; Vonberg, Ralf-Peter; Dorsch, Martina; Mueller-Heine, Annika; Chalaris, Athena; Scheller, Jürgen; Rose-John, Stefan; Seegert, Dirk; Krettek, Christian; Waetzig, Georg H. (June 20, 2011). "Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model". Critical Care Medicine. 39 (6): 1407–1413. doi:10.1097/CCM.0b013e318211ff56. PMID 21336117. S2CID 25703610.
  14. ^ Zhang, Hong; Neuhöfer, Patrick; Song, Liang; Rabe, Björn; Lesina, Marina; Kurkowski, Magdalena U.; Treiber, Matthias; Wartmann, Thomas; Regnér, Sara; Thorlacius, Henrik; Saur, Dieter; Weirich, Gregor; Yoshimura, Akihiko; Halangk, Walter; Mizgerd, Joseph P.; Schmid, Roland M.; Rose-John, Stefan; Algül, Hana (March 20, 2013). "IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality". The Journal of Clinical Investigation. 123 (3): 1019–1031. doi:10.1172/JCI64931. PMC 3582130. PMID 23426178.
  15. ^ Paige, Ellie; Clément, Marc; Lareyre, Fabien; Sweeting, Michael; Raffort, Juliette; Grenier, Céline; Finigan, Alison; Harrison, James; Peters, James E.; Sun, Benjamin B.; Butterworth, Adam S.; Harrison, Seamus C.; Bown, Matthew J.; Lindholt, Jes S.; Badger, Stephen A.; Kullo, Iftikhar J.; Powell, Janet; Norman, Paul E.; Scott, D. Julian A.; Bailey, Marc A.; Rose-John, Stefan; Danesh, John; Freitag, Daniel F.; Paul, Dirk S.; Mallat, Ziad (February 20, 2019). "Interleukin-6 Receptor Signaling and Abdominal Aortic Aneurysm Growth Rates". Circulation: Genomic and Precision Medicine. 12 (2): e002413. doi:10.1161/CIRCGEN.118.002413. PMC 6383754. PMID 30657332.
  16. ^ Schmidt, Stefanie; Schumacher, Neele; Schwarz, Jeanette; Tangermann, Simone; Kenner, Lukas; Schlederer, Michaela; Sibilia, Maria; Linder, Markus; Altendorf-Hofmann, Annelore; Knösel, Thomas; Gruber, Elisabeth S.; Oberhuber, Georg; Bolik, Julia; Rehman, Ateequr; Sinha, Anupam; Lokau, Juliane; Arnold, Philipp; Cabron, Anne-Sophie; Zunke, Friederike; Becker-Pauly, Christoph; Preaudet, Adele; Nguyen, Paul; Huynh, Jennifer; Afshar-Sterle, Shoukat; Chand, Ashwini L.; Westermann, Jürgen; Dempsey, Peter J.; Garbers, Christoph; Schmidt-Arras, Dirk; Rosenstiel, Philip; Putoczki, Tracy; Ernst, Matthias; Rose-John, Stefan (April 2, 2018). "ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signaling". The Journal of Experimental Medicine. 215 (4): 1205–1225. doi:10.1084/jem.20171696. PMC 5881468. PMID 29472497.
  17. ^ Brooks, Gavin D.; McLeod, Louise; Alhayyani, Sultan; Miller, Alistair; Russell, Prudence A.; Ferlin, Walter; Rose-John, Stefan; Ruwanpura, Saleela; Jenkins, Brendan J. (February 15, 2016). "IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis". Cancer Research. 76 (4): 866–876. doi:10.1158/0008-5472.CAN-15-2388. PMID 26744530.
  18. ^ "DRKS - Deutsches Register Klinischer Studien (German Clinical Trials Register)". www.drks.de.
  19. ^ "CLINICAL TRIAL PROTOCOL" (PDF). Retrieved 2024-06-02.
  20. ^ Schreiber S, Aden K, Bernardes JP, Conrad C, Tran F, Höper H, Mishra N, Blase J, Nikolaus S, Bethge J, Kühbacher T, Röcken C, Chen M, Cottingham I, Petri N, Rasmussen BB, Lokau J, Garbers C, Rose-John S, Waetzig GH and Rosenstiel P (2021) Therapeutic gp130 trans-signalling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease. Gastroenterology 160(7):2354-2366; DOI: 10.1053/j.gastro.2021.02.062
  21. ^ Chen BL, Zhang S, Wang B, Chen H, Li Y, Cao Q, Zhong J, Xie M, Ran Z, Tang T, Yang M, Guo T, Xu B, Cai Z, Ma LJ, Schreiber S, Chen MH (2021) Olamkicept, an IL-6 Trans-Signaling Inhibitor, is Effective for Induction of Response and Remission in A Randomized, Placebo-Controlled Trial in Moderate to Severe Ulcerative Colitis. Gastroenterology 161(2) E28-E29
Retrieved from "https://wiki.riteme.site/w/index.php?title=Olamkicept&oldid=1226941543"